Physicians currently have no targeted treatment options available for women diagnosed with an aggressive form of breast cancer known as triple-negative breast cancer , leaving standard-of-care chemotherapies as a first line of defense against the disease. However, most women with TNBC do not respond to these broadly-targeted chemotherapies, and those who do often develop resistance to the drugs.